Compare Ascendis Pharma A/S (ASND) vs Advanced Drainage Systems Inc (WMS) Price & Performance

Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.

The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.

Advanced Drainage Systems (WMS) trades at $150.47, up 1.77% today, with a bullish technical signal and strong fundamental profitability. Recent quarters show consistent earnings beats, with Q1 2026 EPS of $1.07 exceeding the $0.936 estimate. The company maintains robust margins, including a 38.27% gross profit margin and 13.98% net income margin, while cash flow trends indicate solid operational performance despite a net outflow in 2025.

The outlook is positive with a consensus price target of $183.33, suggesting 22% upside, supported by analyst buy ratings. Risks include competitive pressures and a recent Zacks Strong Sell rating, but strong ROE of 24.02% and debt-to-asset improvement to 34.34% in 2025 highlight financial health. Investors should weigh growth potential against market volatility and execution risks.